Study wrapper · #139
Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
Editor's note
A narrative "translational perspective" proposing, but not testing, the idea of using GLP-1 receptor agonists (semaglutide, tirzepatide) as a metabolic-optimization adjunct in prehabilitation before major surgery. The authors are refreshingly candid that there is currently no direct evidence supporting this use; the piece argues biological plausibility (metabolic optimization, sarcopenic obesity, oncologic and bariatric context) while flagging a concrete perioperative safety concern, delayed gastric emptying and aspiration risk, and pointing to current anesthetic guidance. Weight this as hypothesis-generating commentary, not evidence: it maps a research agenda rather than reporting outcomes. The value is in framing the open questions and the safety trade-offs; any clinical use in this setting would require prospective trials of feasibility, safety and meaningful outcomes, which do not yet exist.
Plain-language abstract
This is an opinion-style review, not a study with results. It explores whether GLP-1 medicines such as semaglutide and tirzepatide might be useful before major abdominal surgery, as part of "prehabilitation", getting patients into better shape beforehand to improve recovery. The authors lay out why this idea makes biological sense, including improving metabolism and addressing the combination of obesity with low muscle, and they discuss possible relevance to cancer surgery and to bariatric surgery. They also stress an important safety issue: these drugs slow stomach emptying, which can raise the risk of inhaling stomach contents during anesthesia, and they point to current anesthesia guidance on this. Crucially, they note there is no direct evidence yet that using these drugs for surgical prehabilitation helps. They frame it as a promising but untested idea that needs proper prospective studies.